Silexion Doses First Patient in Phase 2/3 Trial of SIL204 for Pancreatic Cancer
SLXN is trading near its 52-week low of $0.236 (12% above the low) on elevated volume (26× avg).
Summary
Silexion announced the first patient has been dosed in its Phase 2/3 trial of SIL204 for locally advanced pancreatic cancer, marking the start of active clinical execution for its lead program.
Key Events · Product Development and Regulatory · SLXN
-
First Patient Dosed in Phase 2/3 Trial
First patient worldwide dosed with SIL204 at Tel Aviv Sourasky Medical Center (Ichilov) in the Phase 2/3 trial for locally advanced pancreatic cancer.
-
Trial Design and Enrollment Targets
Trial includes an initial safety run-in cohort of approximately 18 patients, followed by a randomized expansion cohort of approximately 166 patients comparing SIL204 plus chemotherapy versus chemotherapy alone.
-
Dual-Route Delivery Strategy
SIL204 is administered via EUS-guided intratumoral injection to penetrate tumor stroma plus subcutaneous abdominal injections for systemic exposure against micro-metastases.
-
Site Activation Underway
Additional oncology centers in Israel and Germany are progressing through site activation and expected to join the program in the coming months.
Analysis · SLXN · Life Sciences
Silexion has moved its lead RNAi candidate SIL204 into active clinical testing, dosing the first patient in a global Phase 2/3 trial for locally advanced pancreatic cancer. This is a real operational milestone for a company that has been fighting for survival — the timeline shows a rejected share authorization, a Nasdaq delisting notice, and going-concern doubts. Positive clinical execution is one of the few levers left to rebuild investor confidence and potentially support a higher valuation or future financing.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 29.2% of the 1503 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.39%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SLXN was trading at $0.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.5M. The 52-week trading range was $0.24 to $42.60. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.